Tilray shares jump as stock buying pressure builds

Traders Union
All News
Financial News
Tilray rises 2.98% today to $5.37

Highlights

Tilray reported a quarterly loss of $0.24 per share with revenue falling short of analyst expectations.
The company expanded its UK medical cannabis and digital health footprint through the acquisition of Lyphe Group.
Tilray’s share price remains under sustained bearish momentum, with a short-term trading range expected between $5.19 and $5.64 amid mixed oversold signals and resistance from technical indicators.

Quarterly loss and UK expansion as sentiment weighs on outlook

Tilray recently reported a quarterly loss of $0.24 per share along with revenue results that missed market expectations. The company completed its acquisition of Lyphe Group, expanding its medical cannabis and digital health presence in the United Kingdom. Additionally, Tilray's beverage division launched BrewDog's largest-ever summer campaign to strengthen its position in the UK drinks and hospitality sector.

Anton Kharitonov, expert at Traders Union, notes that Tilray Brands continues to trade well below all major moving averages, signaling prolonged weakness. He emphasizes that the recent earnings miss and ongoing bearish technical momentum point to persistent downside pressure. The lack of meaningful dynamic support, oversold readings on multiple oscillators, and a negative news backdrop further raise red flags for would-be buyers. Kharitonov is skeptical of any near-term recovery, given the dominance of sellers and absence of strong turnaround indicators. "Risks remain heightened, and I see little justification for aggressive positions at these levels," he warns.

Viktoras Karapetjanc, expert at Traders Union, sees the Lyphe Group acquisition as a key driver for Tilray's expansion in the UK medical cannabis and health market. He believes that the energetic push in beverages, highlighted by the BrewDog summer campaign, shows management's focus on growth and diversification. Even though revenue lagged expectations, the bullish structure remains intact, offering several forward-looking opportunities if the company leverages these assets. "I expect Tilray's strategic moves to unlock further upside as global cannabis markets evolve," he states.

Jainam Mehta, market strategist, observes a strong bearish trend for Tilray, but sees signs of short-term exhaustion among sellers. He notes that technical oscillators are oversold, suggesting a possible relief bounce if price breaks above $5.64. Mehta also considers current sentiment neutralizing, with base case pointing to consolidation. "A contrarian setup could emerge if bears lose momentum and resistance at $5.64 is cleared," he advises.

Bear pressure persists amid resistance at Kijun and mixed signals

Tilray is under persistent downward pressure, trading significantly below major moving averages — 20-day at $5.99, 50-day at $6.42, and 200-day at $9.71 — reflecting a sustained bearish trend for short, medium, and long terms. The immediate resistance sits near the Ichimoku Kijun line at $7.22, with no nearby dynamic support visible on this indicator. Technical momentum remains largely negative: both the MACD and ADX show weak or bearish signals, while oversold readings appear on the RSI, Stochastic RSI, and CCI without triggering a reversal. Bull/Bear Power (BBP) below zero confirms seller dominance, and its oversold view hints at potential short-term exhaustion for bears. The Awesome Oscillator supports the downside bias. Despite a modest opening gap higher and the stock holding toward the top of today's range, mixed signals from oscillators and trend indicators keep the overall momentum uncertain.

Earlier, analysts noted that Tilray was experiencing persistent bearish momentum despite recent efforts to expand its presence in the UK and beverage sector. The current technical and fundamental landscape confirms continued downside risk, making the $5.19 support a pivotal level to monitor for any renewed selling pressure in the near term.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.